Capricor Therapeutics Stock Surges on B.Riley Upgrade Ahead of FDA Decision

Capricor Therapeutics (NASDAQ: CAPR) stock surged 9.2% in pre-market trading to $9.14 after a significant analyst upgrade, bucking a broader market downturn. The move was driven by B.Riley Financial, which reversed its cautious stance on the biotechnology company ahead of a critical regulatory decision.

A Skeptic Turns Bullish

B.Riley upgraded Capricor Therapeutics to Buy from a previous Neutral rating and dramatically increased its price target. The firm's action is a notable reversal, as it had been one of the most cautious voices on Wall Street regarding the stock.

• New Rating: Buy (from Neutral)
• New Price Target: $21 (from $5)

The upgrade centers on what B.Riley described as an "asymmetric opportunity" leading into the November 22, 2026, PDUFA date for deramiocel. This is the deadline for the U.S. Food and Drug Administration (FDA) to decide on the approval of Capricor's investigational cell therapy for Duchenne muscular dystrophy (DMD).

Broadening Wall Street Consensus

Ad

The move by B.Riley aligns the firm with other analysts who have already adopted a bullish outlook on Capricor. This growing consensus follows the FDA's acceptance of a major amendment to the company's biologics license application (BLA) for deramiocel.

Other investment banks with positive ratings include Cantor Fitzgerald (Overweight, $28 target), Piper Sandler (Overweight, $25 target), and Oppenheimer (Outperform, $54 target). B.Riley's upgrade removes a key skeptical voice and signals stronger institutional alignment behind the therapy's potential.

Market Context and Upcoming Catalysts

Capricor's rally occurred despite negative sentiment in the wider market, with the Nasdaq, S&P 500, and Dow all trading lower in the pre-market session. This underscores that the stock's performance was driven entirely by company-specific news.

Investors are now focused on two key dates. The first is the World Muscle Society conference on October 3, 2026, where the company is expected to present open-label extension data that could further influence sentiment. The second is the November 22 PDUFA decision date, which remains the most significant catalyst for the company. The stock's wide 52-week range of $2.96 to $40.37 reflects the high volatility associated with its regulatory journey.